Use of ustekinumab after other biological therapies in moderate-severe psoriasis: Real long-term data

Objective: Ustekinumab is used in moderate-severe plaque psoriasis with inadequate response to anti- tumour necrosis factor α drugs. Recent studies support the need to assess real long-term data. The aim of this study was to evaluate the real long-term effectiveness and safety of ustekinumab...

Full description

Saved in:
Bibliographic Details
Main Authors: Manuel David Gil-Sierra, Esmeralda Ríos-Sánchez, María del Pilar Briceño-Casado
Format: Article
Language:English
Published: Elsevier 2020-09-01
Series:Farmacia Hospitalaria
Subjects:
Online Access:http://www.aulamedica.es/fh/pdf/11420.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!